Patients’ Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)

References

• Mannucci PM, Tuddenham EGD. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187–197. doi:10.1016/S0140-6736(15)01123-X
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis. 2012;7(1):24. doi:10.1186/1750-1172-7-24
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Smit C, Briët E. Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol. 1991;62(1):5–15. doi:10.1007/BF01714977
   Web of Science ®Google Scholar
• Berntorp E. Haemophilia treatment in 2030. Haemophilia. 2016;22(Suppl 5):15–19. doi:10.1111/hae.13025
   Web of Science ®Google Scholar
• Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370(9585):439–448. doi:10.1016/S0140-6736(07)61199-4
   PubMed Web of Science ®Google Scholar
• DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007;138(3):305–315. doi:10.1111/j.1365-2141.2007.06657.x
   PubMed Web of Science ®Google Scholar
• Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom haemophilia centre doctors organisation. Br J Haematol. 2006;133(6):591–605. doi:10.1111/j.1365-2141.2006.06087.x
   Web of Science ®Google Scholar
• Westesson LM, Sparud‐Lundin C, Baghaei F, et al. Burden on parents of children with haemophilia: the impact of sociodemographic and child’s medical condition. J Clin Nurs. 2019;28(21‑22):4077–4086. doi:10.1111/jocn.15003
   Web of Science ®Google Scholar
• Lorenzato CS, Santos RB, Fagundes GZZ, Ozelo MC. Haemophilia Experiences, Results and Opportunities (HERO study) in Brazil: assessment of the psychosocial effects of haemophilia in patients and caregivers. Haemophilia. 2019;25(4):640–650. doi:10.1111/hae.13774
   Web of Science ®Google Scholar
• Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper DL. Impact of haemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies. Haemophilia. 2021;27(Suppl 1):8–16. doi:10.1111/hae.14251
   Web of Science ®Google Scholar
• Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia. 2017;23(4):556–565. doi:10.1111/hae.13214
   PubMed Web of Science ®Google Scholar
• Osooli M, Steen Carlsson K, Baghaei F, et al. The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. Haemophilia. 2017;23(3):e180–e187. doi:10.1111/hae.13231
   Web of Science ®Google Scholar
• Novais T, Duclos A, Varin R, Lopez I, Chamouard V. Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers. Int J Clin Pharm. 2016;38(1):61–69. doi:10.1007/s11096-015-0207-z
   Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: a prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019;25(3):382–391. doi:10.1111/hae.13731
   PubMed Web of Science ®Google Scholar
• Skinner MW, Myles E. World Federation of Hemophilia: 50 years of advancing treatment for all. Haemophilia. 2013;19(4):475–480. doi:10.1111/hae.12200
   PubMed Web of Science ®Google Scholar
• Page D. Comprehensive care for hemophilia and other inherited bleeding disorders. Transfus Apher Sci. 2019;58(5):565–568. doi:10.1016/j.transci.2019.08.005
   PubMed Web of Science ®Google Scholar
• Hoots K. Comprehensive care for hemophilia and related inherited bleeding disorders: why it matters. Curr Hematol Rep. 2003;(2):395–401. Available from: https://www.researchgate.net/publication/10603031_Comprehensive_care_for_hemophilia_and_related_inherited_bleeding_disorders_Why_it_matters  .
   Google Scholar
• Leroy V, Freyssenge J, Renard F, Tazarourte K, Négrier C, Chamouard V. Access to treatment among persons with hemophilia: a spatial analysis assessment in the Rhone-Alpes region, France. J Am Pharm Assoc. 2019;59(6):797–803. doi:10.1016/j.japh.2019.07.006
   Google Scholar
• Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: innovations in hemophilia therapy. Am J Hematol. 2021;96(1):128–144. doi:10.1002/ajh.26018
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630–640. doi:10.1016/S0140-6736(20)32722-7
   PubMed Web of Science ®Google Scholar
• Spadarells G, Di Minno A, Milan G, et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev. 2020;39(39):100618. doi:10.1016/j.blre.2019.100618
   Web of Science ®Google Scholar
• Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R. A molecular revolution in the treatment of hemophilia. Mol Ther. 2020;28(4):997‑1015. doi:10.1016/j.ymthe.2019.11.006
   Web of Science ®Google Scholar
• Khair K, Pollard D, Harrison C, Hook S, O’Driscoll M, Holland M. HOw patients view extended half-life products: impressions from real-world experience (The HOPE study). Haemophilia. 2019;25(5):814–820. doi:10.1111/hae.13803
   PubMed Web of Science ®Google Scholar
• Wells JR, Gater A, Marshall C, Tritton T, Vashi P, Kessabi S. Exploring the impact of infusion frequency in hemophilia a: exit interviews with patients participating in BAY 94-9027 extension studies (PROTECT VIII). Patient. 2019;12(6):611‑9. doi:10.1007/s40271-019-00374-x
   Google Scholar
• Mühlbacher AC, Sadler A, Lamprecht B, Juhnke C. Patient preferences in the treatment of hemophilia a: a best-worst scaling case 3 analysis. Value Health. 2020;23(7):862–869. doi:10.1016/j.jval.2020.02.013
   Web of Science ®Google Scholar
• Kempton C, Trask P, Parnes A, et al. Development and testing of the satisfaction questionnaire with intravenous or subcutaneous hemophilia injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021;27(2):221–228. doi:10.1111/hae.14222
   Web of Science ®Google Scholar
• Hart DP, Kessler CM, Aledort L. Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology. 2019;24(1):737–741. doi:10.1080/16078454.2019.1687798
   PubMed Web of Science ®Google Scholar
• Trinchero A, Sholzberg M, Matino D. The evolution of hemophilia care: clinical and laboratory advances, opportunities, and challenges. Hamostaseologie. 2020;40(3):311–321. doi:10.1055/a-1175-6530
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018;24(Suppl 6):15–21. doi:10.1111/hae.13510
   PubMed Web of Science ®Google Scholar
• Spadarella G, Di Minno A, Brunetti-Pierri N, Mahlangu J, Di Minno G. The evolving landscape of gene therapy for congenital haemophilia: an unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021;46:100737. doi:10.1016/j.blre.2020.100737
   Web of Science ®Google Scholar
• Lvovschi VE, Maignan M, Tazarourte K, et al. Multiple criteria decision analysis approach to consider therapeutic innovations in the emergency department: the methoxyflurane organizational impact in acute trauma pain. PLoS One. 2020;15(4):e0231571. doi:10.1371/journal.pone.0231571
   Web of Science ®Google Scholar
• Berger M, Séchet R. Accessibilité et parcours de soins des hémophiles: analyses à partir du cas de la Bretagne [Accessibility and care pathways for hemophiliacs: analyzes based on the case of Bretagne, France]. Cah Geogr Que. 2011;55(156):511–527. French.
   Google Scholar
• Desanti R, Cardon P. Initiation À L’enquête Sociologique [Initiation to the Sociological Survey]. 1st ed. Rueil-Malmaison: Lamarre; 2010. French.
   Google Scholar
• Huston P, Rowan M. Qualitative studies. Their role in medical research. Can Fam Physician. 1998;(44):2453–2458.
   Google Scholar
• Bréchon P. Enquêtes Qualitatives, Enquêtes Quantitatives [Qualitative Surveys, Quantitative Surveys]. 1st ed. Grenoble: Presses universitaires de Grenoble; 2011. French.
   Google Scholar
• Blanchet A, Gotman A. L’enquête Et Ses Méthodes: L’entretien [The Survey and Its Methods: The Interview]. 2nd ed. Paris: Armand Colin; 2007. French.
   Google Scholar
• Haute Autorité de Santé. Protocole national de diagnostic et de soins Hémophilie [national hemophilia management and diagnostic protocol]. Lyon: Reference Center on Hemophilia and other constitutional hemorrhagic diseases, French network on inherited bleeding disorders MHEMO; 2019. Available from: https://www.has-sante.fr/jcms/c_483032/fr/hemophilie. Accessed February 28, 2021. French.
   Google Scholar
• Mirat W. Suivi INterprofessionnel des PATients atteints de cancer (Etude SINPATIC): une étude exploratoire auprès de patients [INTER-professional follow-up of PATIents with cancer (SINPATIC study): an exploratory study on patients] [doctoral dissertation]. Creteil: University of Paris Est; 2018. French.
   Google Scholar
• Hannane A, Misane L, Devouassoux G, Colin C, Letrilliart L. Asthma patients’ perception on their care pathway: a qualitative study. NPJ Prim Care Respir Med. 2019;29(1):1–8. doi:10.1038/s41533-019-0121-2
   Web of Science ®Google Scholar
• Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107–115. doi:10.1111/j.1365-2648.2007.04569.x
   PubMed Web of Science ®Google Scholar
• Pope C, Ziebland S, Mays N. Qualitative research in helth care. Analysing qualitative data. BMJ. 2000;320(7227):114–116. doi:10.1136/bmj.320.7227.114
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi:10.1191/1478088706qp063oa
   Google Scholar
• Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237–246. doi:10.1177/1098214005283748
   Web of Science ®Google Scholar
• van Overbeeke E, Michelsen S, Hauber B, et al. Patient perspectives regarding gene therapy in haemophilia: interviews from the PAVING study. Haemophilia. 2020;27(1):129–136. doi:10.1111/hae.14190
   Web of Science ®Google Scholar
• van Balen EC, Wesselo ML, Baker BL, et al. Patient perspectives on novel treatments in haemophilia: a qualitative study. Patient. 2020;13(2):201–210. doi:10.1007/s40271-019-00395-6
   PubMedGoogle Scholar
• van Balen EC, Krawczyk M, Gue D, et al. Patient-centred care in haemophilia: patient perspectives on visualization and participation in decision-making. Haemophilia. 2019;25(6):938‑45. doi:10.1111/hae.13830
   Web of Science ®Google Scholar
• Carricaburu D. Innovation thérapeutique et acceptabilité du risque iatrogène: l’introduction des produits antihémophiliques concentrés dans les années soixante-dix [Therapeutic innovation and acceptability of iatrogenic risk: the introduction of concentrated antihemophilic products in the 1970s]. Sci Soc Sante. 1999;17(4):75‑98. French.
   Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349‑57. doi:10.1093/intqhc/mzm042
   Web of Science ®Google Scholar